amgen

“This is where money goes to die,” has described one sector over the past decade but this year, things are different. That industry is health care and for the first time since 1988, it leads the S&P with a 12 percent gain—the most among the 10 main groups. Specifically, health insurers,...

On Wednesday, Spectrum Pharmaceuticals (NASDAQ: SPPI) dropped 37 percent after releasing its Q1 and full year revenue guidance. The company said it expects sales of its colorectal cancer drug, Fusilev, to total $80 to $90 million in 2013 compared to $204 million in 2012. Seem like a huge drop...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of February. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of February. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ: ILMN) and Vertex Pharmaceuticals (NASDAQ: VRTX) grew somewhat between the January 31...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the latter two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Vertex Pharmaceuticals (NASDAQ: VRTX) and VIVUS...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex...

The focus was on the big banks last week, with Goldman Sachs (NYSE: GS), J.P. Morgan (NYSE: JPM) and Morgan Stanley (NYSE: MS) reporting strong results, but Bank of America (NYSE: BAC) and Citigroup (NYSE: C) not so much. The spotlight is on tech earnings this week. Analysts anticipate lower per-...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of December. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN) and Illumina (NASDAQ: ILMN) grew somewhat between the...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of November. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Illumina (NASDAQ: ILMN) and Regeneron Pharmaceuticals (NASDAQ: REGN) grew somewhat between the November 15 and...

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of October. Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between...

The short interest in biotech and emerging pharmaceutical companies was mixed in the first two weeks of October. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ...

After largely rising in the previous period, short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of September. Shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN), Onyx...

The short interest data is out from the September 14 settlement date. By and large, short sellers have resumed their gambles on biotech firms compared to the August 31 settlement date. Short interest had waned for the most part in the two weeks before the end of August. Two notable exceptions to...

The short interest data is out from the August 31 settlement date. By and large short sellers have retreated from gambles on biotech firms, compared to the August 15 settlement date. A few notable exceptions were Amgen (NASDAQ: AMGN), for which short interest was higher by 8.8 percent to 12.8...